PCM
TBIO

Penn Capital Management’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Penn Capital Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,800
Closed -$633K – 168
2023
Q3 		$633K Buy
33,800
+1,604
+5% +$39K 0.06% 129
2023
Q2 		$916K Buy
32,196
+1,958
+6% +$78.2K 0.09% 127
2023
Q1 		$1.69M Sell
30,238
-34,988
-54% -$1.24M 0.17% 119
2022
Q4 		$1.47M Buy
65,226
+11,445
+21% +$311K 0.15% 131
2022
Q3 		$1.61M Buy
53,781
+24,646
+85% +$868K 0.18% 121
2022
Q2 		$944K Buy
+29,135
New +$2.01M 0.1% 144

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return